HANISON (00896) Announces Interim Results with Net Loss of HK$86.743 million, Narrowed by 68.41% Year-on-Year
HANISON (00896) announced its interim results for the six months ended September 30, 2026. The Group recorded revenue of HK$807 million, up 4.75% year-on-year; net loss of HK$86.743 million, narrowed by 68.41% year-on-year; and loss per share of 8.1 HK cents.
HANISON (00896) announced its interim results for the six months ended September 30, 2026. The Group recorded revenue of HK$807 million, up 4.75% year-on-year; net loss of HK$86.743 million, narrowed by 68.41% year-on-year; and loss per share of 8.1 HK cents.
Related Articles
NICHE-TECH SEMI (08490): KLF Accountancy Limited Resigns as Auditor
Tianqi Lithium Corporation (002466.SZ): The verification report on lithium ore resource reserves in the Cuola mining area has passed review and filing.
VIGONVITA-B(02630): The New Drug Application (NDA) for Angweida Sildenafil Citrate Tablets has been accepted by the Department of Health of Hong Kong, China and the Pharmaceutical Administration Bureau of Macau, China
NICHE-TECH SEMI (08490): KLF Accountancy Limited Resigns as Auditor
Tianqi Lithium Corporation (002466.SZ): The verification report on lithium ore resource reserves in the Cuola mining area has passed review and filing.
VIGONVITA-B(02630): The New Drug Application (NDA) for Angweida Sildenafil Citrate Tablets has been accepted by the Department of Health of Hong Kong, China and the Pharmaceutical Administration Bureau of Macau, China
